Researchers at Colorado State University have developed a new device and method for repairing large, “critical” bone defects. The system combines a highly porous, osteogenic scaffold with a biodegradable sleeve that integrates with standard fixation plates, enabling faster native bone growth. It uses materials that are already used clinically and allows 3D-printing to match patient-specific sizes. The approach has been demonstrated in a large-animal model and shows accelerated integration and remodeling compared to existing treatments. This innovation holds promise for both human and veterinary orthopedic applications.
Large bone defects—those that will not heal spontaneously—pose a major complication in both human and veterinary orthopedics, often following trauma or tumor removal. Traditional treatment relies on permanent metal plates and grafts, which carry high rates of infection, poor integration, reoperation and implant-related complications. The novel system addresses a persistent need: a regenerative solution that can support load, stimulate bone formation, and eventually disappear, reducing long-term implant burdens.
The technology developed by the Colorado State University team is built around two main components: a highly porous scaffold and a complementary biodegradable sleeve that attaches to a standard metal fixation plate. The scaffold is made of anorganic (deproteinized) bone mineral (ABM) and is 3D-printed to achieve ~70 % porosity, enabling deep ingrowth of new bone. Because scaffold alone cannot address mechanical stability and micro-motion at the defect site (which slows healing), the biodegradable sleeve provides immobilization and supports the scaffold, while the fixation plate takes the load. In a pilot study in sheep, this endoprosthetic “system” demonstrated faster integration of the scaffold-host bone interface, more mature new bone formation inside the scaffold pores, and faster remodeling of the scaffold into new bone compared to other treatments. All materials selected are already used in FDA-approved applications in other contexts, which streamlines translation toward human use.
Available for Licensing
TRL: 5
David Prawel
Bernard Seguin
Connor Witt
Steve Foster
Steve.Foster@colostate.edu
970-491-7100